Veradermics, Incorporated (MANE) Stock Price & How to Invest

Veradermics, Inc. (NYSE: MANE) is a New Haven, Connecticut biopharmaceutical company founded in 2019 and focused on dermatology and aesthetics. Its lead candidate, VDPHL01, is a proprietary oral, extended-release formulation of minoxidil designed to boost hair regrowth while limiting the cardiac exposure associated with existing oral minoxidil use. The company has completed enrollment in a roughly 519-patient Phase 2/3 study for male pattern hair loss that showed statistically significant hair-count gains versus placebo, and has additional registrational work underway: a confirmatory Phase 3 study in men ('304) with topline data expected in the second half of 2026, 12-month data from the '302 study on the same timeline, and a fully enrolled 556-patient registration-directed study in women ('306) with topline data expected in the first half of 2027. An open-label Phase 2 study in women ('207) reported positive six-month hair-count results in July 2026. A smaller pipeline includes VDMN (a dissolvable microarray patch for common warts), VDAA (alopecia areata), and VDMC (molluscum contagiosum).

The investment picture is defined by the fact that Veradermics has no approved product and effectively no product revenue. After a February 2026 IPO at $17 and a follow-on plus private placement in April 2026, the company raised roughly $766 million in aggregate during 2026, and it held about $819.9 million of cash, equivalents and marketable securities at June 30, 2026, which management says funds current plans into 2030. Second-quarter 2026 net loss was about $23.5 million, or $0.58 per share against a $0.64 consensus loss, as R&D rose to $18.6 million and G&A to $10.9 million on commercial-readiness work. The stock has been extraordinarily volatile: it closed near $108.40 on October 16, 2026, up about 187% from its first 2026 trading level and inside a 52-week range of roughly $32.00 to $136.72, for a market value near $4.5 billion carried entirely on clinical expectations. Hair-loss drug developers became a crowded trade in late summer 2026, and an insider sold about $10.7 million of stock in August. The next quarterly report is expected around November 12, 2026. As with any pre-revenue biotech, the range of outcomes is very wide, and the eventual result depends on trial data, FDA decisions, commercial execution, and competition.

Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $104 million on a trailing basis as of mid-2026) and depends on clinical and regulatory success it has not yet achieved. The valuation, a multibillion-dollar market cap on essentially zero revenue, leaves little room for disappointment, and the shares have been extremely volatile since the IPO. Value is concentrated in VDPHL01, meaning a failed registrational trial, a safety signal, or an FDA setback could sharply impair the company. Even with approval, it would compete against cheap generic minoxidil and finasteride and against telehealth platforms like Hims & Hers, Keeps, and Ro. Future capital raises could dilute existing shareholders.

6 analysts publish price targets on MANE, averaging $163.50 against a $108.82 price as of October 2026, or +50.2%. The published targets run from $135.00 to $182.00, a narrow spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MANE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Veradermics, Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Large, underserved hair-loss market. Pattern hair loss affects a very large population, and existing options are dominated by decades-old generics (topical minoxidil, oral finasteride) and cash-pay telehealth. The most optimistic published target, $182.00, assumes this works close to its best case.

The case against. Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $104 million on a trailing basis as of mid-2026) and depends on clinical and regulatory success it has not yet achieved. The most pessimistic target, $135.00, is roughly what MANE is worth if this bites instead.

Read the full bull and bear case on MANE, including what would have to change to break either one. Walnut is not an investment adviser.

No. Veradermics, Incorporated (MANE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veradermics, Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-commercial)
• Net loss (TTM): ~$104M; Q2 2026 ~$23.5M
• EPS: Q2 2026 ~$(0.58) vs ~$(0.64) consensus; trailing ~$(4.24)
• Cash & securities: ~$820M at Jun 30, 2026; runway guided into 2030
• Market cap and price: ~$4.5B at ~$108.40 (Oct 16, 2026)
• Price / book: ~5.6x

Traditional valuation multiples do not apply because Veradermics has no product revenue and posts consistent losses; the roughly $4.5 billion market value reflects expectations for VDPHL01 rather than current financials. About $820 million of cash covers a meaningful share of that value, so the market is assigning roughly $3.7 billion to the pipeline ahead of registrational readouts. The stock has swung across a 52-week range of roughly $32 to $137 since its February 2026 IPO at $17, and six covering analysts average a target near $163.50.

Other names that sit close to MANE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MANE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MANE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MANE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MANE is a richly valued, pre-commercial biotech whose value hinges almost entirely on whether VDPHL01 reaches the market, which makes it a high-volatility, binary-outcome holding.

Whether MANE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MANE a buy or a sell?, and where the stock could go from here in the MANE stock forecast.

For income investors, whether MANE pays a dividend and how the payout looks is covered in does MANE pay a dividend? And to weigh MANE against a peer, read the full side-by-side comparisons: MANE vs HIMS and MANE vs MRNA.